Mouse models of cancer.
暂无分享,去创建一个
[1] W. Murray. A NOTE ON OVARIAN SECRETION AND CANCER. , 1928, Science.
[2] A. Tannenbaum,et al. The influence of the degree of caloric restriction on the formation of skin tumors and hepatomas in mice. , 1949, Cancer research.
[3] V. Jordan. Effects of tamoxifen in relation to breast cancer. , 1977, British medical journal.
[4] P. Hunsicker,et al. Specific-locus test shows ethylnitrosourea to be the most potent mutagen in the mouse. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[5] P. Leder,et al. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes , 1984, Cell.
[6] R. Palmiter,et al. Transgenic mice harboring SV40 t-antigen genes develop characteristic brain tumors , 1984, Cell.
[7] M. Zijlstra,et al. Involvement of c‐myc in MuLV‐induced T cell lymphomas in mice: frequency and mechanisms of activation. , 1984, The EMBO journal.
[8] D. Hanahan,et al. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. , 1985, Nature.
[9] A. Berns,et al. Proviral activation of the putative oncogene Pim‐1 in MuLV induced T‐cell lymphomas. , 1985, The EMBO journal.
[10] R. Palmiter,et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.
[11] A. Knudson,et al. Genetics of human cancer. , 1986, Annual review of genetics.
[12] R. Hoess,et al. The role of the loxP spacer region in P1 site-specific recombination. , 1986, Nucleic acids research.
[13] M. Capecchi,et al. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells , 1987, Cell.
[14] N. Copeland,et al. Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors , 1988, Molecular and cellular biology.
[15] A. Berns,et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors , 1989, Cell.
[16] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[17] H. Pitot,et al. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. , 1990, Science.
[18] Philippe Soriano,et al. Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. , 1991, Genes & development.
[19] A. Berns,et al. Carcinogen-induced lymphomagenesis in pim-1 transgenic mice: dose dependence and involvement of myc and ras. , 1991, Cancer research.
[20] Anton Berns,et al. Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging , 1991, Cell.
[21] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[22] R. Weinberg,et al. Effects of an Rb mutation in the mouse , 1992, Nature.
[23] K. Kinzler,et al. Erratum: Multiple Intestinal Neoplasia Caused By a Mutation in the Murine Homolog of the APC Gene , 1992, Science.
[24] P. Demant. Genetic resolution of susceptibility to cancer--new perspectives. , 1992, Seminars in cancer biology.
[25] R. Weinberg,et al. Tumor spectrum analysis in p53-mutant mice , 1994, Current Biology.
[26] B. Koller,et al. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities , 1996, Nature Genetics.
[27] J. Rossant,et al. The Tumor Suppressor Gene Brca1 Is Required for Embryonic Cellular Proliferation in the Mouse , 1996, Cell.
[28] G M Edelman,et al. Targeted DNA recombination in vivo using an adenovirus carrying the cre recombinase gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[29] W F Bodmer,et al. Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[30] James M. Roberts,et al. The murine gene p27Kip1 is haplo-insufficient for tumour suppression , 1998, Nature.
[31] R. Xavier,et al. Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.
[32] P. Pharoah,et al. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours , 1999, Genes, chromosomes & cancer.
[33] Thomas Ried,et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation , 1999, Nature Genetics.
[34] T. van Dyke,et al. Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice. , 1999, Cancer research.
[35] Philippe Soriano. Generalized lacZ expression with the ROSA26 Cre reporter strain , 1999, Nature Genetics.
[36] G. Evan,et al. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. , 1999, Molecular cell.
[37] S. Kogan,et al. Retinoic Acid and Arsenic Synergize to Eradicate Leukemic Cells in a Mouse Model of Acute Promyelocytic Leukemia , 1999, The Journal of experimental medicine.
[38] L. Chin,et al. Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.
[39] D. Hanahan,et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.
[40] M. Scott,et al. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice , 1999, Nature Medicine.
[41] P. Pandolfi,et al. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[42] E. Sandgren,et al. Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice , 2000, Oncogene.
[43] R. Plasterk,et al. Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. , 2000, Journal of molecular biology.
[44] Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. , 2000, Cancer research.
[45] Caiying Guo,et al. Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon cre‐mediated excision , 2000, Genesis.
[46] G. Merlino,et al. Accelerated ultraviolet radiation-induced carcinogenesis in hepatocyte growth factor/scatter factor transgenic mice. , 2000, Cancer research.
[47] A. Trumpp,et al. Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP‐mediated recombination in the mouse , 2000, EMBO reports.
[48] Curtis C. Harris,et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis , 2001, Nature Genetics.
[49] A. Bradley,et al. Engineering chromosomal rearrangements in mice , 2001, Nature Reviews Genetics.
[50] A. Balmain,et al. Building 'validated' mouse models of human cancer. , 2001, Current opinion in cell biology.
[51] A. Berns,et al. Mouse models for sporadic cancer. , 2001, Experimental cell research.
[52] T. Jacks,et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.
[53] T. Jacks,et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.
[54] H. Varmus,et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. , 2001, Genes & development.
[55] H. Ruley,et al. Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase , 2001, Nature Biotechnology.
[56] A. Buchmann,et al. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of β-catenin-mutated mouse liver tumors , 2001, Oncogene.
[57] F. Gage,et al. Delivery of the Cre recombinase by a self-deleting lentiviral vector: Efficient gene targeting in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[58] P. Duray,et al. Neonatal sunburn and melanoma in mice , 2001, Nature.
[59] T. Jacks,et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[60] Adrian L. Harris,et al. Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.
[61] David Baltimore,et al. Germline Transmission and Tissue-Specific Expression of Transgenes Delivered by Lentiviral Vectors , 2002, Science.
[62] A. West,et al. Insulators: many functions, many mechanisms. , 2002, Genes & development.
[63] Jos Jonkers,et al. Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. , 2002, Cancer research.
[64] H. Varmus,et al. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. , 2002, Cancer cell.
[65] Cestmir Vlcek,et al. Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers , 2002, Nature Genetics.
[66] Susumu Minamisawa,et al. ErbB2 is essential in the prevention of dilated cardiomyopathy , 2002, Nature Medicine.
[67] P. Demant,et al. Cancer susceptibility in the mouse: genetics, biology and implications for human cancer , 2003, Nature Reviews Genetics.
[68] D. Largaespada,et al. Gene transfer into genomes of human cells by the sleeping beauty transposon system. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[69] T. Pawson,et al. Transgenic RNA interference in ES cell–derived embryos recapitulates a genetic null phenotype , 2003, Nature Biotechnology.
[70] Robert A. Weinberg,et al. Comparative Biology of Mouse versus Human Cells: Modelling Human Cancer in Mice O P I N I O N , 2022 .
[71] N. Greenberg,et al. SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis. , 2003, Molecular cancer therapeutics.
[72] E. Petricoin,et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.
[73] C. Conti,et al. Advances in molecular carcinogenesis: current and future use of mouse models to screen and validate molecularly targeted anticancer drugs , 2004, Molecular carcinogenesis.
[74] C. Perou,et al. MYC Is Amplified in BRCA1-Associated Breast Cancers , 2004, Clinical Cancer Research.
[75] E. Holland,et al. Somatic Cell Gene Transfer , 2004 .
[76] G. Rao,et al. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice , 2004, Oncogene.
[77] Carl-Fredrik Tiger,et al. Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[78] P. Pandolfi,et al. Germline Modification Strategies , 2004 .
[79] P. Sharp,et al. Cre-lox-regulated conditional RNA interference from transgenes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[80] Oriol Casanovas,et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.
[81] Corey M. Carlson,et al. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse , 2005, Nature.
[82] S. Lyons. Advances in imaging mouse tumour models in vivo , 2005, The Journal of pathology.
[83] A. Berns,et al. Retroviral insertional mutagenesis: past, present and future , 2005, Oncogene.
[84] D. Largaespada,et al. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system , 2005, Nature.
[85] T. Jacks,et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer , 2005, Nature Medicine.
[86] Robert D. Cardiff,et al. Selective Evolution of Stromal Mesenchyme with p53 Loss in Response to Epithelial Tumorigenesis , 2005, Cell.
[87] J. Mesirov,et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis , 2005, Nature Genetics.
[88] David A Largaespada,et al. Hopping around the tumor genome: transposons for cancer gene discovery. , 2005, Cancer research.
[89] Min Han,et al. Efficient Transposition of the piggyBac (PB) Transposon in Mammalian Cells and Mice , 2005, Cell.
[90] J. Nadeau,et al. The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours , 2005, Nature.
[91] L. Luo,et al. Mosaic Analysis with Double Markers in Mice , 2005, Cell.
[92] X. Coumoul,et al. Conditional knockdown of Fgfr2 in mice using Cre-LoxP induced RNA interference , 2005, Nucleic acids research.
[93] P. Pharoah,et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1 , 2005, Nature Genetics.
[94] M. Wilkinson,et al. Tissue-specific RNAi reveals that WT1 expression in nurse cells controls germ cell survival and spermatogenesis. , 2006, Genes & development.
[95] R. DePinho,et al. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[96] Takeshi Suzuki,et al. Tumor suppressor gene identification using retroviral insertional mutagenesis in Blm‐deficient mice , 2006, The EMBO journal.
[97] Rudolf Jaenisch,et al. Efficient method to generate single‐copy transgenic mice by site‐specific integration in embryonic stem cells , 2006, Genesis.
[98] A. Berns,et al. Cross-Species Oncogenomics in Cancer Gene Identification , 2006, Cell.
[99] L. Chin,et al. Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene , 2006, Cell.
[100] Ronald A. DePinho,et al. Model organisms: The mighty mouse: genetically engineered mouse models in cancer drug development , 2006, Nature Reviews Drug Discovery.
[101] M. Wigler,et al. Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach , 2006, Cell.
[102] D. Xing,et al. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. , 2006, Cancer research.
[103] G. Evan,et al. Tumor angiogenesis: cause or consequence of cancer? , 2007, Cancer research.
[104] A. Bradley,et al. Generation of an inducible and optimized piggyBac transposon system , 2007, Nucleic acids research.
[105] L. Luo. Fly MARCM and mouse MADM: Genetic methods of labeling and manipulating single neurons , 2007, Brain Research Reviews.
[106] A. Bradley,et al. Induced mitotic recombination of p53 in vivo , 2007, Proceedings of the National Academy of Sciences.
[107] L. Luo,et al. Modeling sporadic loss of heterozygosity in mice by using mosaic analysis with double markers (MADM) , 2007, Proceedings of the National Academy of Sciences.
[108] P. Polakis. The many ways of Wnt in cancer. , 2007, Current opinion in genetics & development.
[109] Sen Wu,et al. Toward simpler and faster genome-wide mutagenesis in mice , 2007, Nature Genetics.
[110] H. Vogel,et al. CHD5 Is a Tumor Suppressor at Human 1p36 , 2007, Cell.
[111] G. Lucignani,et al. Cancer modeling: modern imaging applications in the generation of novel animal model systems to study cancer progression and therapy. , 2007, The international journal of biochemistry & cell biology.
[112] David A. Tuveson,et al. Maximizing mouse cancer models , 2007, Nature Reviews Cancer.
[113] Heidi Zhang,et al. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. , 2007, Journal of proteome research.
[114] L. Chin,et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers , 2007, Nature.
[115] David Bouchez,et al. Manipulating the Mouse Embryo , 2007 .
[116] J. Hughes,et al. Manipulating the Mouse Genome to Engineer Precise Functional Syntenic Replacements with Human Sequence , 2007, Cell.
[117] S. Lowe,et al. Tissue-specific and reversible RNA interference in transgenic mice , 2007, Nature Genetics.
[118] G. Evan,et al. Distinct thresholds govern Myc's biological output in vivo. , 2008, Cancer cell.
[119] S. Hanash,et al. Mining the plasma proteome for cancer biomarkers , 2008, Nature.
[120] S. Hayward,et al. Prostate tumor progression is mediated by a paracrine TGF-β/Wnt3a signaling axis , 2008, Oncogene.
[121] A. Krasnitz,et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. , 2008, Genes & development.
[122] A. Krasnitz,et al. An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer , 2008, Cell.
[123] Jeffrey S. Han,et al. Conditional activation of a single‐copy L1 transgene in mice by Cre , 2008, Genesis.
[124] Michelle A. Anderson,et al. A Mouse to Human Search for Plasma Proteome Changes Associated with Pancreatic Tumor Development , 2008, PLoS medicine.
[125] C. Yeang,et al. Combinatorial patterns of somatic gene mutations in cancer , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[126] Robert M. Hoffman,et al. Imaging cancer dynamics in vivo at the tumor and cellular level with fluorescent proteins , 2008, Clinical & Experimental Metastasis.
[127] Kazushi Inoue,et al. MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer , 2009, Expert review of molecular diagnostics.
[128] Akira Niwa,et al. Direct Hematological Toxicity and Illegitimate Chromosomal Recombination Caused by the Systemic Activation of CreERT21 , 2009, The Journal of Immunology.
[129] Liese C C Pruitt,et al. Integrated Proteomic Analysis of Human Cancer Cells and Plasma from Tumor Bearing Mice for Ovarian Cancer Biomarker Discovery , 2009, PloS one.
[130] T. Scheetz,et al. A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. , 2009, Cancer research.
[131] J. Downing,et al. Mouse models of human AML accurately predict chemotherapy response. , 2009, Genes & development.
[132] David J. Adams,et al. Cancer gene discovery in mouse and man , 2009, Biochimica et biophysica acta.
[133] M. Habiba,et al. The effects of tamoxifen and estradiol on myometrial differentiation and organization during early uterine development in the CD1 mouse. , 2009, Reproduction.
[134] Yoichi Gondo,et al. Next-generation gene targeting in the mouse for functional genomics. , 2009, BMB reports.
[135] M. Katoh,et al. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. , 2009, Current molecular medicine.
[136] Eyal Gottlieb,et al. Metabolic transformation in cancer. , 2009, Carcinogenesis.
[137] Y. Asmann,et al. A Transposon-Based Genetic Screen in Mice Identifies Genes Altered in Colorectal Cancer , 2009, Science.
[138] G. Vassiliou,et al. New approaches for modelling sporadic genetic disease in the mouse , 2009, Disease Models & Mechanisms.
[139] S. Hanash,et al. Comprehensive Proteome Analysis of an Apc Mouse Model Uncovers Proteins Associated with Intestinal Tumorigenesis , 2009, Cancer Prevention Research.
[140] A. Krasnitz,et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. , 2009, Cancer cell.
[141] L. Luo,et al. Uncoupling Dendrite Growth and Patterning: Single-Cell Knockout Analysis of NMDA Receptor 2B , 2009, Neuron.
[142] Derek Y. Chiang,et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma , 2009, Nature Biotechnology.
[143] L. Chin,et al. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family– and KRAS-dependent lung adenocarcinomas , 2010, Nature Biotechnology.